Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
OTCMKTS:MYCOF

Mydecine Innovations Group (MYCOF) Stock Price, News & Analysis

→ Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad)
Free MYCOF Stock Alerts
$0.01
+0.00 (+44.55%)
(As of 05/17/2024 08:55 PM ET)
Compare
Today's Range
$0.0055
▼
$0.0146
50-Day Range
$0.00
▼
$0.02
52-Week Range
$0.00
▼
$0.26
Volume
118,900 shs
Average Volume
20,992 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartHeadlinesShort Interest
MYCOF stock logo

About Mydecine Innovations Group Stock (OTCMKTS:MYCOF)

Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

MYCOF Stock Price History

MYCOF Stock News Headlines

May 17 at 3:22 AM | finanznachrichten.de
Mydecine Innovations Group Inc - Mydecine Provides Bl-Weekly Status Report
May 16, 2024 | stockhouse.com
Mydecine Provides Bl-Weekly Status Report
May 4, 2024 | stockhouse.com
Mydecine Announces Intention to Refile Certain Financial Statements and Applies for Management Cease Trade Order
May 3, 2024 | finanznachrichten.de
Mydecine Innovations Group Inc - Mydecine applies for management cease trade order
May 3, 2024 | finanznachrichten.de
Mydecine Innovations Group Inc - Management cease trade order
April 18, 2024 | finance.yahoo.com
Mydecine Innovations Group Inc (0NF0.BE)
April 17, 2024 | finance.yahoo.com
Mydecine Innovations Group Inc (0NF0.MU)
April 17, 2024 | stockhouse.com
Mydecine Innovations Group Inc. Announces Closing Of Share For Debt Settlement
April 9, 2024 | uk.finance.yahoo.com
Mydecine Innovations Group Inc - SHARE FOR DEBT SETTLEMENT
March 28, 2024 | uk.finance.yahoo.com
Mydecine Innovations Group Inc - Mydecine Innovations Group Inc. Announces Closing of Share for Debt Settlement
March 20, 2024 | finance.yahoo.com
Mydecine Innovations Group Inc. Announces Share for Debt Settlement
February 7, 2024 | finance.yahoo.com
Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds
February 2, 2024 | finance.yahoo.com
Mydecine Innovations Group Announces Director Resignation
December 18, 2023 | uk.finance.yahoo.com
Mydecine Innovations Group Inc - Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound
December 18, 2023 | finance.yahoo.com
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound
November 29, 2023 | finanznachrichten.de
Mydecine Innovations Group Inc.: Mydecine Announces Update Regarding the Special Access Program
November 28, 2023 | finance.yahoo.com
Mydecine Announces Update Regarding the Special Access Program
November 17, 2023 | finance.yahoo.com
Canadian Securities Exchange Reports October 2023 Performance Figures
October 31, 2023 | finance.yahoo.com
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements
October 26, 2023 | finanznachrichten.de
Mydecine Innovations Group Inc.: Mydecine Provides Q4 2023 Business Update
October 26, 2023 | financialpost.com
Mydecine Provides Q4 2023 Business Update
October 25, 2023 | lse.co.uk
Mydecine Innovations Group Inc Share Price (MYIG.PL)
October 16, 2023 | proactiveinvestors.com
Mydecine Innovations Group gearing up for human trials after completing Aquis listing
October 13, 2023 | finanznachrichten.de
Mydecine Innovations Group Inc - Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK
October 12, 2023 | benzinga.com
Psychedelic-Based Drugs Biotech Company Begins Trading On UK's AQSE Growth Market
See More Headlines

Company Calendar

Last Earnings
11/16/2021
Today
5/20/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
OTCMKTS:MYCOF
CUSIP
N/A
CIK
N/A
Web
www.mydecine.com
Phone
(604) 687-2038
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. David Joshua Bartch (Age 36)
    Co-Founder, CEO, President & Chairman of the Board
    Comp: $322.62k
  • Mr. Robert Roscow M.A.
    Co-Founder, Chief Scientific Officer & Director
  • Mr. Damon Michaels
    Co-Founder & COO
  • Mr. John Charles Ross CA (Age 66)
    CPA, M.B.A., CFO & Corporate Secretary
    Comp: $6.68k
  • Mr. Sanford M. Stein
    Chief Compliance Officer & General Counsel
  • Dr. Rakesh Jetly FRCPC
    M.D., Chief Medical Officer
  • Morgan Kervitsky
    Director of Marketing
  • Mr. Michel Rudolphie
    President of the European Operations
  • Mr. William Cook
    Interim CEO & Technical Director of Mindleap Health Inc.

Key Competitors

View All Competitors

MYCOF Stock Analysis - Frequently Asked Questions

How have MYCOF shares performed in 2024?

Mydecine Innovations Group's stock was trading at $0.0149 at the beginning of 2024. Since then, MYCOF shares have decreased by 2.0% and is now trading at $0.0146.
View the best growth stocks for 2024 here.

How were Mydecine Innovations Group's earnings last quarter?

Mydecine Innovations Group Inc. (OTCMKTS:MYCOF) posted its earnings results on Tuesday, November, 16th. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.50.

When did Mydecine Innovations Group's stock split?

Shares of Mydecine Innovations Group reverse split on the morning of Thursday, April 21st 2022. The 1-50 reverse split was announced on Thursday, April 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Mydecine Innovations Group?

Shares of MYCOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:MYCOF) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Elon to Transform U.S. Economy?
Porter & Company
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
"The Biggest Drug Ever" Is Coming
Behind the Markets
Most important medical advance in 100 years
The Oxford Club
Does this make you sick?
Allegiance Gold
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star